However, for each of these markers of type I IFN, inflammation, tumor cell immune susceptibility, and immune cell activation, we did not observe any significant differences in gene expression between the groups treated with CpG+OX40 vs. RT+CpG+OX40. The gene discussed is TNFRSF4; the disease is neoplasm.